| Net loss | |
| Depreciation and amortization | 45.76M |
| Non-cash restructuring and other costs | |
| Amortization of premium on investments | 925K |
| Stock-based compensation expense | 29.19M |
| Unrealized loss on Put Rights | |
| Unrealized holding gain for trading securities | |
| Non-cash tax benefit | |
| Other gain | 261K |
| Accounts receivable | 33.04M |
| Inventories, net | -61.08M |
| Prepaid expenses and other assets | -1.63M |
| Deferred inventory costs | |
| Accounts payable | -13.94M |
| Accrued liabilities and other expenses | -7.58M |
| Deferred revenue | -805K |
| Accrued warranty | |
| Net cash provided by (used in) operating activities | |
| Purchase of available-for-sale investments | -118.02M |
| Purchase of cost-method investment | |
| Proceeds from sale of available-for-sale investments | 0 |
| Proceeds from maturities and calls of investments | |
| Proceeds from disposal of assets | |
| Purchase of property and equipment | -32.88M |
| Advance to secure manufacturing capacity | |
| Reimbursement of manufacturing capacity advance | |
| Change in restricted cash | -4.95M |
| Net cash used in investing activities | |
| Proceeds from issuance of common stock | 16.49M |
| Repurchase of common stock | |
| Payments for purchase of assets under financing arrangement | |
| Net cash provided by financing activities | |
| Effect of exchange rate changes on cash | -1.42M |
| Net change in cash and cash equivalents | -18.11M |
| Cash and cash equivalents at beginning of period | 149.1M |
| Cash and cash equivalents at end of period | 131M |
| Cash paid for income taxes | 5.56M |